Incyte Corporation
Incyte Reports Strong Q3 2024 Financial Results and Pipeline Updates
Summary
Incyte Corporation announced its third-quarter 2024 financial results, showcasing a 24% year-over-year increase in total revenues to $1,138 million. Key highlights include a 16% rise in Jakafi net product revenues to $741 million and a 52% surge in Opzelura net product revenues to $139 million. The company also provided updates on its clinical pipeline, such as the FDA approval of Niktimvo for chronic graft-versus-host disease and positive data for several investigational drugs. Incyte raised its full-year 2024 Jakafi revenue guidance and updated its R&D guidance to include a milestone payment to MacroGenics.
Profitelligence Alerts
Get alerts for INCY
Be first to know when Incyte Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Incyte Corporation
Incyte Corporation is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. With a focus on oncology and inflammation, Incyte aims to address significant unmet medical needs through its robust portfolio of proprietary compounds. The company's flagship product, a therapeutic for certain types of blood cancers, underscores its pivotal role in cancer treatment paradigms. Incyte also invests heavily in research and development, maintaining a pipeline of next-generation treatments in various stages of clinical trials. Having established strategic partnerships with leading global pharmaceutical companies, Incyte leverages collaborative efforts to enhance its research capabilities and market presence. Headquartered in Wilmington, Delaware, Incyte Corporation is a key player in the biopharmaceutical sector, significantly contributing to advancements in medical science and patient care through its commitment to innovation and therapeutic excellence.
Official SEC Documents
Advertisement